Details for Patent: 7,592,329

Title:	Crystalline complexes of fluticasone-2-furoate
Abstract:	There is provided a crystalline complex comprising a compound of formula (I) ##STR00001## in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P2.sub.12.sub.12.sub.1 having unit cell dimensions of about 12.5.+-.1.0 .sctn., 15.+-.1.0 .sctn., and 16.2.+-.1.0 .sctn. when determined at either 120K or 150K.
Inventor(s):	Biggadike; Keith (Stevenage, GB), Coote; Steven John (Stevenage, GB), Craig; Andrew (Tonbridge, GB), Crowe; David Malcolm (Tonbridge, GB), Jacewicz; Victor Witold (Tonbridge, GB), Millan; Michael John (Tonbridge, GB), Nice; Rosalyn Kay (Stevenage, GB), Noga; Brian (Durham, NC), Seager; John Frederick (Stevenage, GB), Theophilus; Andrew Lewis (Ware, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Filing Date:	Feb 04, 2003
Application Number:	10/503,114
Claims:	1. A crystalline complex comprising a compound of formula (I) ##STR00009## in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P2.sub.12.sub.12.sub.1 having unit cell dimensions of about 12.5.+-.1.0 .ANG., 15.+-.1.0 .ANG., and 16.2.+-.1.0 .ANG. when determined at either 120K or 150K, wherein the guest molecule comprises one or more of t-butylamine, cyclohexanone, pyridine, butylamine, cyclohexylamine, or .epsilon.-caprolactam. 2. A complex according to claim 1 wherein the guest molecule is liquid at ambient temperature and pressure. 3. A complex according to claim 1 wherein the guest molecule is .epsilon.-caprolactam. 4. A complex according to claim 1 wherein the guest molecule is selected from the group consisting of t-butylamine and cyclohexylamine. 5. A complex according to claim 1 wherein the guest molecule is cyclohexanone. 6. A complex according to claim 1 wherein the guest molecule is pyridine. 7. A complex according to claim 1 wherein the guest molecule is t-butylamine. 8. A complex according to claim 1 wherein the guest molecule is cyclohexylamine. 9. A complex according to claim 1 wherein the molar ratio of compound of formula (I) to guest molecule is 1:2.0 to 1:0.3. 10. A pharmaceutical composition comprising a complex according to claim 1 together with a physiologically acceptable diluent or carrier.